Emerald Investment Advisers’s Dianthus Therapeutics DNTH Stock Holding History

Emerald Investment Advisers’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.58M	Buy	+26,459	New	+$2.31M	0.17%	167

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Emerald Investment Advisers's DNTH Position: Q2 2026 in Review

Emerald Investment Advisers opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 26,459 shares worth $2.58M. The stake represents 0.17% of the portfolio and ranks #167 among its holdings.

267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Emerald Investment Advisers held 26,459 shares of Dianthus Therapeutics worth $2.58M as of Q2 2026.
Dianthus Therapeutics was a new Emerald Investment Advisers position in Q2 2026.
Dianthus Therapeutics made up 0.17% of Emerald Investment Advisers's portfolio in Q2 2026, its #167 holding.
267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Emerald Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.